Novavax Management

Management criteria checks 1/4

Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 1.25 years. directly owns 0.031% of the company’s shares, worth MX$3.03M. The average tenure of the management team and the board of directors is 1.3 years and 3.7 years respectively.

Key information

John Jacobs

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	0.03%
Management average tenure	1.3yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO

John Jacobs (56 yo)

1.3yrs

Tenure

Mr. John Charles Jacobs, M.B.A., served as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Trizzino	President & COO	less than a year	US$3.08m	0.020% $ 2.0m
James Kelly	Executive VP	2.7yrs	US$3.08m	0.0095% $ 933.6k
Stanley Erck	Advisor	1.3yrs	US$8.40m	0.026% $ 2.6m
John Jacobs	CEO & Director	1.3yrs	no data	0.031% $ 3.0m
Richard Crowley	Executive VP & COO	1.3yrs	no data	no data
Troy Morgan	Senior VP & Chief Compliance Officer	no data	no data	no data
Mark Casey	Executive VP	less than a year	no data	no data
Erika Trahan	Associate Director of Investor & Public Relations	6yrs	no data	no data
Ian Watkins	Executive VP & Chief Human Resources Officer	less than a year	no data	no data
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.3yrs	no data	no data
Filip Dubovsky	President of Research & Development	3.8yrs	no data	0.048% $ 4.7m
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.2yrs	no data	0.010% $ 999.5k

1.3yrs

Average Tenure

58yo

Average Age

Experienced Management: NVAX *'s management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
John Jacobs	CEO & Director	1.3yrs	no data	0.031% $ 3.0m
David Mott	Independent Director	3.8yrs	US$380.56k	0.031% $ 3.1m
Richard Douglas	Independent Director	14.3yrs	US$382.56k	0.027% $ 2.6m
Margaret McGlynn	Independent Director	3.3yrs	US$369.17k	0.0027% $ 267.6k
Gregg Alton	Independent Director	3.5yrs	US$378.06k	0.0027% $ 267.6k
Rachel King	Independent Director	5.4yrs	US$368.54k	0.0088% $ 860.8k
Richard Rodgers	Independent Director	1.5yrs	US$639.51k	0.0027% $ 267.6k
James Young	Independent Chairman of the Board	14yrs	US$561.55k	0.050% $ 4.9m

3.7yrs

Average Tenure

61yo

Average Age

Experienced Board: NVAX *'s board of directors are considered experienced (3.7 years average tenure).

Novavax Management

Management criteria checks 1/4

Key information

Recent management updates

Novavax, Inc. Announces Changes to Executive Leadership Team

High number of new directors

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc., Annual General Meeting, Jun 16, 2022

Independent Chairman of the Board recently sold Mex$18m worth of stock

Recent updates

No longer forecast to breakeven

Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022)

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

New minor risk - Profitability

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$6.53 loss in 2Q 2022)

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

New minor risk - Profitability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$3.41 loss per share (vs US$2.66 profit in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$8.42 loss per share (vs US$23.44 loss in FY 2021)

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax Covid-19 Vaccine as A Primary Series for Adults Aged 18 and Older

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as A Booster for Adults Aged 18 and Older

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

Novavax Nuvaxovid COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Novavax, Inc. Nuvaxovid™ Covid-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Novavax, Inc. announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as First and Second Booster for Adults

Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Forecast breakeven date pushed back to 2023

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

Second quarter 2022 earnings released: US$6.53 loss per share (vs US$4.75 loss in 2Q 2021)

Novavax, Inc. Initiates Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years

Novavax, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc. COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

Novavax, Inc. Announces European Commission Approves Expanded Conditional Marketing Authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine in European Union for Adolescents Aged 12 Through 17

Novavax, Inc. Presents Data At FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants